The FDA advisory committee endorsed Abbott's TriClip TEER system for severe tricuspid regurgitation based on data from the TRILUMINATE trial. The trial showed significant improvements in valve dysfunction and quality of life for patients who underwent the repair. Safety was a key highlight, with a high percentage of patients free from major adverse events post-procedure. The panel members expressed confidence in the device's safety and effectiveness, emphasizing the importance of understanding patient benefits and proper training for optimal outcomes.
To Another Language
from source content
www.medscape.com
Key Insights Distilled From
by Megan Brooks at www.medscape.com 02-15-2024
https://www.medscape.com/viewarticle/fda-panel-favor-triclip-tricuspid-regurgitation-2024a100037nDeeper Inquiries